Louisiana is currently home to 893 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
AltaValve Early Feasibility Study Protocol
NCT03997305
Recruiting
Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Cardiovascular Institute of the South, Houma, Louisiana
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
Register for Updates
OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study
NCT05405374
Recruiting
The objective of this clinical study is to compare OSTEOAMP SELECT Fibers to Infuse Bone Graft, in terms of effectiveness and safety, when used as a bone graft substitute in in skeletally mature patients qualified for 2-lumbar interbody fusion (LIF) by means of an intra-patient control model.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/25/2023
Locations: Spine Institute of Louisiana, Shreveport, Louisiana
Conditions: Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease
Register for Updates
Phase 2 Clinical Trial of CartiLife® in the United States
NCT04744402
Recruiting
To evaluate the safety and efficacy of implanting pellet-type extracellular matrix-associated autologous chondrocytes (CartiLife®) obtained by cultivating costal chondrocytes of the subject with articular cartilage defects of the knee as a result of trauma or degeneration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/24/2023
Locations: Lafayette General Health, Lafayette, Louisiana
Conditions: Articular Cartilage Defect, Articular Cartilage Degeneration
Register for Updates
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
NCT03631225
Recruiting
The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability. Optimal management requires regular assessment of disease activity, with treatment changes made as needed for optimal efficacy. Vectra is a blood serum test that looks at 12 biomarkers and produces a score on a scale of 1 to 100. The Vectra score has been shown to be the strongest predictor of risk for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: Accurate Clinical Research, Lake Charles, Louisiana
Conditions: Rheumatoid Arthritis (RA)
Register for Updates
Venetoclax and Lintuzumab-Ac225 in AML Patients
NCT03867682
Recruiting
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana
Conditions: Acute Myeloid Leukemia, Relapsed Adult AML
Register for Updates
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
NCT05303636
Recruiting
The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in comparison to non-hormonal contraceptive methods. Secondary objectives include further evaluating the impact of LF111 and DRSP 3.5 mg chewable tablets on BMD and bone turnover after 12 months (13 medication cycles) in comparison to non-hormonal contraceptive methods and a... Read More
Gender:
FEMALE
Ages:
Between 14 years and 45 years
Trial Updated:
06/15/2023
Locations: Tandem Clinical Research, Marrero, Louisiana
Conditions: Change in Bone Mineral Density, Bone Loss
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Tulane Cancer Center Office of Clinical Research, New Orleans, Louisiana
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
TIVA vs TXA in Sinus Surgery to Evaluate Operative Blood Loss and Surgical Field Quality
NCT05639686
Recruiting
The goal of this interventional study is to compare the efficacy (surgical field quality and intra-operative blood loss) or cost of TIVA alone to general inhalational anesthetics with intravenous TXA in patient participants who are undergoing endoscopic sinus surgery. The main questions the study aims to answer are: * Is the surgical field quality better when using TIVA alone compared to general inhalational anesthetics with intravenous TXA? * Is one method more financially advantageous to the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2023
Locations: Our Lady of the Lake Hospital, Baton Rouge, Louisiana
Conditions: Rhinosinusitis Chronic, Sinus Cancer, Sinus Polyp, Encephalocele
Register for Updates
Increasing PrEP With Trans Women in the Deep South
NCT05689281
Recruiting
The goal of this to address barriers and facilitators to PrEP uptake, and encourage adherence among trans women via a single arm stepped wedge clinical trial. The main question is to compare PrEP uptake and adherence outcomes among trans women in the T'Cher intervention to the delayed study arm.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: NO/AIDS Task Force d.b.a. CrescentCare, New Orleans, Louisiana
Conditions: Hiv
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Spine Institute of Louisiana, Shreveport, Louisiana
Conditions: Symptomatic Cervical Disc Disease
Register for Updates
REFINE Study: A Study In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
NCT05504499
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of the use of Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material in fusion in patients with chronic low back pain that present with degenerative disc disease with concurrent neurogenic claudication.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2022
Locations: Koga Neurosurgery, Slidell, Louisiana
Conditions: Lumbar Spinal Stenosis
Register for Updates
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT05211856
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, New Orleans, Louisiana
Conditions: Chronic Lymphocytic Leukemia
Register for Updates